Sucampo, Takeda make Amitiza deal global
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals will get $14m up front and could earn up to $35m in milestone fees based on certain sales targets in exchange for giving Takeda Pharmaceutical global rights to the constipation drug Amitiza (lubiprostone) versus the partners' prior US and Canada agreement.